1. Home
  2. HALO vs PARA Comparison

HALO vs PARA Comparison

Compare HALO & PARA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HALO
  • PARA
  • Stock Information
  • Founded
  • HALO 1998
  • PARA 1986
  • Country
  • HALO United States
  • PARA United States
  • Employees
  • HALO N/A
  • PARA N/A
  • Industry
  • HALO Biotechnology: Biological Products (No Diagnostic Substances)
  • PARA Broadcasting
  • Sector
  • HALO Health Care
  • PARA Industrials
  • Exchange
  • HALO Nasdaq
  • PARA Nasdaq
  • Market Cap
  • HALO 7.4B
  • PARA 7.9B
  • IPO Year
  • HALO N/A
  • PARA N/A
  • Fundamental
  • Price
  • HALO $54.54
  • PARA $11.97
  • Analyst Decision
  • HALO Buy
  • PARA Sell
  • Analyst Count
  • HALO 9
  • PARA 14
  • Target Price
  • HALO $63.56
  • PARA $11.31
  • AVG Volume (30 Days)
  • HALO 3.3M
  • PARA 6.9M
  • Earning Date
  • HALO 05-06-2025
  • PARA 05-08-2025
  • Dividend Yield
  • HALO N/A
  • PARA 1.67%
  • EPS Growth
  • HALO 55.40
  • PARA N/A
  • EPS
  • HALO 3.76
  • PARA N/A
  • Revenue
  • HALO $1,084,306,000.00
  • PARA $28,720,000,000.00
  • Revenue This Year
  • HALO $25.77
  • PARA N/A
  • Revenue Next Year
  • HALO $18.01
  • PARA $0.71
  • P/E Ratio
  • HALO $14.51
  • PARA N/A
  • Revenue Growth
  • HALO 25.64
  • PARA N/A
  • 52 Week Low
  • HALO $42.01
  • PARA $9.54
  • 52 Week High
  • HALO $70.51
  • PARA $13.05
  • Technical
  • Relative Strength Index (RSI)
  • HALO 44.48
  • PARA 59.30
  • Support Level
  • HALO $52.43
  • PARA $11.62
  • Resistance Level
  • HALO $54.26
  • PARA $12.03
  • Average True Range (ATR)
  • HALO 3.42
  • PARA 0.23
  • MACD
  • HALO -0.49
  • PARA 0.01
  • Stochastic Oscillator
  • HALO 30.60
  • PARA 87.76

About HALO Halozyme Therapeutics Inc.

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.

About PARA Paramount Global Class B

Paramount Global operates in three global business segments: TV media, filmed entertainment, and direct to consumer. The TV media business includes television production studios and various broadcast and cable networks, including CBS, 15 owned CBS affiliates, Paramount, Nickelodeon, MTV, BET, and VH1. Filmed entertainment consists multiple film studios, most importantly Paramount Pictures. The film studios produce and distribute movies that they license to movie theaters and other media outlets. Direct to consumer includes the Paramount+, Pluto TV, and BET+ streaming services. Much of the content on Paramount's streaming platforms is created by the production studios housed within the firm's other two business segments.

Share on Social Networks: